| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PDCD1 |
| Clinical data | |
| Trade names | Jemperli |
| Other names | TSR-042, WBP-285, dostarlimab-gxly |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Immunotherapy |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6420H9832N1690O2014S44 |
| Molar mass | 144325.73 g·mol−1 |
Dostarlimab, sold under the brand name Jemperli, is a medication used to treat certain solid tumors such as endometrial cancer.[5] Specifically it is used for mismatch repair deficient (dMMR) recurrent or advanced cancer.[5] Benefits were seen in 44% of cases.[6] It is given by gradual injection into a vein.[6]
Common side effects include tiredness, nausea, diarrhea, and anemia.[5] Other side effects may include joint pain, itching, rash, fever, and low thyroid.[6] Severe side effect may include pneumonitis, colitis and hepatitis due to immune dysfunction.[5] Use during pregnancy may harm the baby.[5] It is a monoclonal antibody which blocks programmed death receptor-1 (PD-1), thus allowing the immune system to kill cancer cells.[5][6]
Dostarlimab was approved for medical use in the United States and Europe in 2021.[5][6] In the United States it costs about 11,400 USD per 500 mg as of 2022.[7] In the United Kingdom this amount costs about £5,900.[8]
References
edit- ^ a b "Jemperli APMDS". Therapeutic Goods Administration (TGA). 2 March 2022. Archived from the original on 19 March 2022. Retrieved 5 March 2022.
- ^ "Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]". Health Canada. 24 January 2022. Archived from the original on 29 May 2022. Retrieved 28 May 2022.
- ^ "Summary Basis of Decision (SBD) for Jemperli". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
- ^ "FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA) (Press release). 22 April 2021. Archived from the original on 22 April 2021. Retrieved 22 April 2021.
This article incorporates text from this source, which is in the public domain.
- ^ a b c d e f g h i j "Jemperli- dostarlimab injection". DailyMed. Archived from the original on 1 March 2022. Retrieved 28 April 2021.
- ^ a b c d e f "Jemperli EPAR". European Medicines Agency (EMA). 24 February 2021. Archived from the original on 14 May 2022. Retrieved 16 July 2021.
- ^ "Jemperli Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 13 June 2022. Retrieved 22 July 2022.
- ^ "Dostarlimab". SPS - Specialist Pharmacy Service. 16 March 2019. Archived from the original on 11 February 2022. Retrieved 22 July 2022.
